Genedata and Roche Extend Collaboration of Biomarker Discovery for Personalized Healthcare

Genedata Expressionist® for Mass Spectrometry license renewal integral to Roche advancement of personalized healthcare; Software will demo at 60th ASMS Conference

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
Genedata Expressionist for Mass Spectrometry gives us automated, workflow-based processing and powerful visualizations – all of which enables our high-quality biomarker identification process.

Vancouver, British Columbia (PRWEB) May 21, 2012

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Roche renewed the licensing agreement of Genedata Expressionist for Mass Spectrometry. Genedata Expressionist is a comprehensive, enterprise-level system for omics data management. Roche will use the system to target molecular pathways and validate novel biomarkers in the field of proteomics. Genedata Expressionist for Mass Spectrometry will be shown at the 60th ASMS Conference on Mass Spectrometry at the Vancouver Convention Centre (May 20 - 24; Suite #16).

“Genedata Expressionist for Mass Spectrometry efficiently supports understanding of disease mechanisms, discovery and validation of biomarkers,” explained Prof. Hanno Langen, head of the Protein and Metabolite Technologies Group at Roche. “We process and analyze extremely large data sets and therefore require reliable, high-throughput, and scalable software to support our innovative mass spec processes. Genedata Expressionist for Mass Spectrometry gives us automated, workflow-based processing and powerful visualizations – all of which enables our high-quality biomarker identification process.”

Thriving on large experimental data sets, Genedata Expressionist for Mass Spectrometry integrates a range of mass spectrometry (MS) technologies including label-free LC-MS/GC-MS, labeled experiments using SILAC, iTRAQ, and TMT, MRM, and Infusion MS. It also provides a rich portfolio of statistical tools that promote understanding of biological systems and diseases. Workflow support includes:

  •     Fragment Analysis
  •     4D Data Experiments
  •     Targeted Analysis
  •     Peptide and Protein Identification with Mascot, SEQUEST, X!Tandem, and TPP

“Using Genedata Expressionist helps us to efficiently support the complex data flow and analysis of the mass spectrometry experiments. Our experience with the software and the company is positive,” noted Dr. Martin Erkens, head of Early Development Informatics, pRED.

“Roche is pioneering personalized healthcare and we take great pride in contributing to this innovative work,” said Dr. Othmar Pfannes, CEO of Genedata. “Moreover, Roche’s use of Genedata Expressionist validates it as the platform of choice for integrated, large-scale data management in biomarker discovery for personalized healthcare.”

About Genedata
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. http://www.genedata.com

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.


Contact